Nipro Pharma Corporation
Nipro Pharma Corporation, a leading player in the pharmaceutical industry, is headquartered in Japan and operates extensively across Asia, Europe, and the Americas. Founded in 1954, the company has established itself as a key provider of high-quality medical products, particularly in the fields of dialysis, infusion therapy, and injectable pharmaceuticals. Nipro's commitment to innovation is evident in its diverse range of core products, which include advanced medical devices and pharmaceutical formulations designed to enhance patient care. The company is recognised for its rigorous quality standards and has achieved significant milestones, including numerous certifications and awards that underscore its market position. With a focus on research and development, Nipro Pharma continues to drive advancements in healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Nipro Pharma Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nipro Pharma Corporation's score of 17 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nipro Pharma Corporation's reported carbon emissions
In 2023, Nipro Pharma Corporation reported total carbon emissions of approximately 524,809,000 kg CO2e, comprising 189,940,000 kg CO2e from Scope 1 and 399,969,000 kg CO2e from Scope 2 emissions. This represents a slight increase from 2022, when total emissions were about 518,347,000 kg CO2e, with Scope 1 emissions at 173,753,000 kg CO2e and Scope 2 emissions at 344,594,000 kg CO2e. For 2024, Nipro Pharma Corporation has disclosed emissions from its Thailand plant, amounting to about 1,000 kg CO2e, although specific Scope categorisation for this data is not provided. Currently, Nipro Pharma Corporation does not have any publicly stated reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. The emissions data is cascaded from its parent company, Nipro Corporation, which is classified as a current subsidiary. Nipro Pharma Corporation's climate strategy appears to be in the early stages, with no significant reduction initiatives or targets reported at this time. The company continues to monitor its emissions and may develop more comprehensive climate commitments in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nipro Pharma Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
